Labiotech.eu

News and Trends 1 Jul 2015

Green light for one of the largest clinical trials in Immunotherapy

In a period, where uncountable big pharmas and biotechs are struggling to get the largest piece of the immunotherapy cake, an unexpected player has arrived. TxCell, a French biotech, received an option to extend its current phase IIb study from EU to US, a stage that lots of immunotherapy experts would like to reach. TxCell was founded fourteen years […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Jun 2015

Stallergenes and Greer to create the World Leader in Allergy Immunotherapy

A few months ago, we were talking about the refusal of Stallergenes’ minority shareholders to merge with Greer laboratories, another competitor within the field of allergy treatment. Finally, Stallergenes shareholders accepted, and both companies are going to create the world leader in allergy immunotherapy. After the sale of Serono to Merck back in 2007, the magnate Ernesto Bertarelli started its […]

June 30, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Transgene, the oldest French Biotech company announced just yesterday that it will cut 120 jobs on its current 300 employees. The company will shut down its manufacturing facility in order to focus on the Research and Development of its therapeutic vaccine candidates. Wise move or final last words? Back in 1976, Robert Swanson and Herbert Boyer founded […]

June 30, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Qiagen vs. Illumina, the next Big Fight in Next-gen Sequencing

Next-gen sequencing is a revolution. San Diego-based Illumina owns most of the market but German giant Qiagen is prepared to disrupt this fact by stepping in massively by the end of the year. The fight has only begun. Imagine you could sequence your genome to discover the disease you may have in the future. What if I told you, […]

June 30, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 29 Jun 2015

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Actelion has created a new start-up in the field of synthetic carbohydrate vaccines, together with the Max Planck Society. Actelion has made a funding commitment of up to €30M to back the new company, Vaxxilon. Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces discovered the first preclinical […]

June 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 29 Jun 2015

Novartis pays €625M for Spinifex’s chronic pain treatment

[Update 06.30.2015] According to an email sent to FierceBiotech by Spinifex’s CEO Tom McCarthy, Novartis could pay an additional $500m (approximately €445m) of future milestones to Spinifex’s shareholders. Spinifex Pharmaceuticals, a US-Australian biotechnology company has just been bought by Novartis. With this acquisition, the Swiss giant aims to control the development of EMA401, a new treatment for […]

June 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 Jun 2015

6 Things the Digital Revolution already Disrupted in the Biotech Industry

2 weeks ago, I was at NOAH15 in Berlin, one of the biggest European events on Digital, gathering key opinion leaders such as Eric Schmidt from Google or Ariana Huffington, founder of the Huffington Post. They all talked about the impact of the recent digital wave, internet and the post-pc area in different industries. Biotech […]

June 29, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 28 Jun 2015

Google and big names helped Oxford Sciences Innovation to raise €457M

Oxford Sciences Innovation has completed the second close of its fundraising, raising an additional €157.3M (£110M) and bringing the total amount raised to €457.6M (£320M). This second close included some well-known investors such as Google Ventures and Charles Dunstone. Being backed by one of the best-recognized institutions in the world has its advantages. Oxford University […]

June 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

AstraZeneca’s senior managers are abandoning ship

In just a couple of weeks, AstraZeneca has seen two of its chiefs leave their position to run two smaller biotechs. James Ward-Lilley made his exist from Astra to become CEO of Vectura, just a few days after Briggs Morrison abruptly left to also become CEO of Syndax. The rich also cry, said the telenovela and […]

June 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 25 Jun 2015

A treatment for Spinal Muscular Atrophy received Orphan Drug designation

The European Medicines Agency has granted Orphan Drug designation to AveXis’ gene transfer candidate. The therapy is currently in clinical development in the United States for the treatment of type 1 Spinal Muscular Atrophy and already received Orphan Drug designation for this disease in the United States. Spinal Muscular Atrophy is an autosomal-recessive genetic disorder […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Green light for one of the largest clinical trials in Immunotherapy

Stallergenes and Greer to create the World Leader in Allergy Immunotherapy

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Qiagen vs. Illumina, the next Big Fight in Next-gen Sequencing

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Novartis pays €625M for Spinifex’s chronic pain treatment

6 Things the Digital Revolution already Disrupted in the Biotech Industry

Google and big names helped Oxford Sciences Innovation to raise €457M

AstraZeneca’s senior managers are abandoning ship

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Video: Discover How CAR-T Therapies are Working

A treatment for Spinal Muscular Atrophy received Orphan Drug designation

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!